Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01121185 · ClinicalTrials.gov registry record · Phase 2
Study in Hepatitis C Virus (HCV) Infected Patients Undergoing Liver Transplantation to Evaluate a Human Monoclonal Antibody Against Hepatitis C
A Phase 2 study, sponsored by MassBiologics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT01121185 is a Phase 2 study that was terminated before completion, run by MassBiologics. The registered enrollment target is 13 participants.
The verdict
NCT01121185, a Phase 2 study, was terminated before completion, sponsored by MassBiologics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether a human monoclonal antibody against Hepatitis C (MBL-HCV1) is effective in preventing detectable levels of Hepatitis C virus in patients undergoing liver transplantation due to chronic HCV infection. The study will also determine if MBL-HCV1 is effective in delaying or reducing the amount of detectable HCV in patients after transplant.
Interventions
- BIOLOGICAL MBL-HCV1
- OTHER 0.9% Sodium chloride Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2010-06 |
| Est. Completion | 2011-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01121185
The ClinicalTrials.gov registry entry for NCT01121185 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MassBiologics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which MBL-HCV1 is the first listed.
NCT01121185 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01121185 about?
NCT01121185 is a clinical study titled "Study in Hepatitis C Virus (HCV) Infected Patients Undergoing Liver Transplantation to Evaluate a Human Monoclonal Antibody Against Hepatitis C". The purpose of this study is to determine whether a human monoclonal antibody against Hepatitis C (MBL-HCV1) is effective in preventing detectable levels of Hepatitis C virus in patients undergoing liver transplantation due to chronic HCV infection. The study will also determine if MBL-HCV1 is effec...
What is the current status of trial NCT01121185?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2010-06. Estimated completion is 2011-06.
What interventions are being tested in trial NCT01121185?
The interventions under investigation include: MBL-HCV1 (BIOLOGICAL), 0.9% Sodium chloride Placebo (OTHER).
Who is sponsoring clinical trial NCT01121185?
This trial is sponsored by MassBiologics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.